For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Rasagiline (Azilect, Azipron) is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.
According to our (Global Info Research) latest study, the global Rasagiline Tablet market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The racemic form of the drug was invented by Aspro Nicholas in the early 1970s. Moussa B.H. Youdim identified it as a potential drug for Parkinson's disease, and working with collaborators at Technion - Israel Institute of Technology in Israel and the drug company, Teva Pharmaceutical, identified the R-isomer as the active form of the drug. Teva brought it to market in partnership with Lundbeck in Europe and Eisai in the US and elsewhere. It was approved in Europe in 2005 and in the US in 2006.
This report is a detailed and comprehensive analysis for global Rasagiline Tablet market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Rasagiline Tablet market size and forecasts, in consumption value ($ Million), sales quantity (M Pcs), and average selling prices (USD/K Pcs), 2018-2029
Global Rasagiline Tablet market size and forecasts by region and country, in consumption value ($ Million), sales quantity (M Pcs), and average selling prices (USD/K Pcs), 2018-2029
Global Rasagiline Tablet market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (M Pcs), and average selling prices (USD/K Pcs), 2018-2029
Global Rasagiline Tablet market shares of main players, shipments in revenue ($ Million), sales quantity (M Pcs), and ASP (USD/K Pcs), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Rasagiline Tablet
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Rasagiline Tablet market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Teva Pharmaceutical, Lundbeck, Sun Pharmaceutical, Apotex and Taj Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Rasagiline Tablet market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- 0.5 mg/Pcs
- 1 mg/Pcs
Market segment by Application
- Under 40 Years Old
- 40-65 Years Old
- Above 65 Years Old
Major players covered
- Teva Pharmaceutical
- Lundbeck
- Sun Pharmaceutical
- Apotex
- Taj Pharma
- Mylan
- Takeda Pharmaceutical
- Sandoz
- Intas Pharmaceuticals
- Natco Pharma
- Ajanta Pharma
- Orchid Pharma
- Alkem Laboratories
Market segment by region, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rasagiline Tablet product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Rasagiline Tablet, with price, sales, revenue and global market share of Rasagiline Tablet from 2018 to 2023.
Chapter 3, the Rasagiline Tablet competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rasagiline Tablet breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Rasagiline Tablet market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Rasagiline Tablet.
Chapter 14 and 15, to describe Rasagiline Tablet sales channel, distributors, customers, research findings and conclusion.